METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling. Sang H, Liu J, Chen X, Zeng Y, et al. BMC Cancer 2025;25:641.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sang H, Liu J, Chen X, Zeng Y, et al. METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling. BMC Cancer 2025;25:641.
PMID: 40200229